UPDATE: GlobeImmune (GBIM) Reports Q1 Loss Per Share of 15c, Continues to Evaluate Strategic Alternatives
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
GlobeImmune Announces Updates and Financial Results for First Quarter 2016
May 12, 2016 6:30 AM EDTLOUISVILLE, CO -- (Marketwired) -- 05/12/16 -- GlobeImmune, Inc. (NASDAQ: GBIM) today provided an update on the Company's business and clinical programs and announced financial results for the first quarter 2016.
The Company continues to seek potential strategic transactions. Cantor Fitzgerald & Co. has been retained by the Company to assist in reviewing ways to maximize stockholder value. There is not a defined timeline for the strategic review process and the review may not result in any specific action or transaction.
The Company has three ongoing clinical... More
